Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial

Kexiang Yan(Huashan Hospital), Jinhua Xu(Yuxian People's Hospital), Aie Xu(Third People's Hospital of Hangzhou), Jiang Meiying(Nanchang University), Siping Zhang(Lanzhou University), Donghua Liu(Guangxi Medical University), Rixin Chen(Nanchang University), Zhenghua Zhang(Fudan University), Xiaohong Zhu(First Affiliated Hospital of Wenzhou Medical University), Fuqiu Li(Second Affiliated Hospital of Jilin University), Kuanhou Mou(First Affiliated Hospital of Xi'an Jiaotong University), Sen Yang(Harbin Medical University), Linfeng Li(Beijing Friendship Hospital), Xin Li(Jimei University), Yanling Li(Hebei Medical University), Shanshan Li(China-Japan Friendship Hospital), Hongyi Li, Xiao Hua Wang(University of Canberra), Chunlei Zhang(Peking University), Ling Han(Fudan University), Xiuping Han(China Medical University), Hao Cheng(Sir Run Run Shaw Hospital), Zhiming Li(Boai Hospital of Zhongshan), Yan Lü(Hebei Medical University), Jianfang Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojing Cui(Jiangsu Hengrui Medicine (China)), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Xiaoyan Bai(Capital Medical University), Yu‐Ye Li(Chinese Academy of Sciences), Jianyun Lu(Central South University), Zudong Meng(People's Hospital of Shiyan), Aijun Chen(Zhejiang University), Wenqing Wang(Nanjing Drum Tower Hospital), Guangchao Dong(Jiangsu Hengrui Medicine (China)), Xiaoyan Yao(Jiangsu Hengrui Medicine (China)), Xiaodong Bi, Yu Wang(Shanghai First Maternity and Infant Hospital), Chao Ji(Zhongshan Hospital of Xiamen University)
Journal of the American Academy of Dermatology
September 26, 2024
Cited by 28


Related Papers